Literature DB >> 17103068

Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.

Carlo Ratto1, Riccardo Ricci, Vincenzo Valentini, Federica Castri, Angelo Parello, Maria A Gambacorta, Numa Cellini, Fabio M Vecchio, Giovanni B Doglietto.   

Abstract

BACKGROUND: Neoplastic microfoci have frequently been found in the mesorectum, with poor outcome. In this study, incidence and clinical significance of mesorectal microfoci (MMF) were analyzed in patients operated on for rectal cancer following neoadjuvant chemoradiation.
METHODS: A case series of 68 patients with extraperitoneal rectal cancer treated with neoadjuvant chemoradiation and surgery (including total mesorectal excision) were investigated for presence of neoplastic MMF.
RESULTS: MMF were found in 26 cases (38.2%). Increasing incidence of microfoci was statistically related to pathologic involvement of the bowel wall (P = 0.0006), Mandard's tumor regression grading (P = 0.0006), and pathologic neoplastic mesorectal involvement (P < 0.00001). None of the nine patients with complete tumor disappearance displayed both microfoci and lymph node metastasis. Only one local recurrence developed in a patient with multiple MMF. One out of nine pT0 or TRG1 patients (11.1%) had distant metastases compared with 15 out of 59 pT1-4 or TRG2-5 (25.4%, P = 0.70).
CONCLUSIONS: A remarkable incidence of MMF was found following chemoradiation. However, when this therapy induced complete regression of primary tumor (pT0-TRG1), we found that node metastases and neoplastic MMF also disappeared. These features should be confirmed to assess the impact of these microfoci in treatment decision making in rectal cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17103068     DOI: 10.1245/s10434-006-9163-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Prognostic value of tumor shrinkage versus fragmentation following radiochemotherapy and surgery for rectal cancer.

Authors:  Monirath Hav; Louis Libbrecht; Karen Geboes; Liesbeth Ferdinande; Tom Boterberg; Wim Ceelen; Piet Pattyn; Claude Cuvelier
Journal:  Virchows Arch       Date:  2015-02-19       Impact factor: 4.064

Review 2.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 3.  Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications.

Authors:  Monirath Hav; Louis Libbrecht; Liesbeth Ferdinande; Karen Geboes; Piet Pattyn; Claude A Cuvelier
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.